UK-18892, a new aminoglycoside: an in vitro study

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Aminoglycoside antibiotics are crucial for treating bacterial infections.
• Emergence of antibiotic resistance, particularly to gentamicin, necessitates development of new agents.
• Amikacin is a widely used aminoglycoside, but resistance remains a concern.

Purpose of the Study:

• To evaluate the antibacterial activity of UK-18892, a novel kanamycin A derivative.
• To compare the spectrum and potency of UK-18892 with amikacin.
• To assess activity against gentamicin-resistant bacterial strains.

Main Methods:

• In vitro susceptibility testing of UK-18892 and amikacin against various pathogenic bacteria.
• Determination of minimum inhibitory concentrations (MICs).
• Evaluation of activity against gentamicin-susceptible and resistant strains of Pseudomonas aeruginosa, Enterobacteriaceae, and Staphylococcus aureus.

Main Results:

• UK-18892 exhibited broad-spectrum activity against a wide range of pathogenic bacteria.
• Activity profile of UK-18892 was similar to amikacin, with minor differences observed.
• UK-18892 showed approximately twofold greater activity than amikacin against gentamicin-susceptible Pseudomonas aeruginosa.
• Both agents were equally effective against gentamicin-resistant P. aeruginosa, Enterobacteriaceae, and Staphylococcus aureus.
• Cross-resistance between UK-18892 and amikacin was noted.

Conclusions:

• UK-18892 is a promising aminoglycoside antibiotic with a spectrum of activity comparable to amikacin.
• Its enhanced potency against certain gentamicin-susceptible P. aeruginosa strains warrants further investigation.
• The observed cross-resistance suggests a similar mechanism of action or resistance development pathway.